Investors are bracing for a Democratic party clean sweep of the White House and both houses of Congress in November's elections and that's bad news for the U.S. bond market. From mobile devices to laptop computers to wifi to factory floors, pretty much everything in our lives runs on semiconductor chips.A look at the numbers will bear this out. Molecular Partners AG has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics across multiple therapeutic areas. (To watch Sharma’s track record, click here)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. For the quarter, sales volume averaged almost 25K barrels of oil equivalent daily.At Wells Fargo, analyst Thomas Hughes is impressed by this company’s balance sheet and production opportunities.“With a net cash balance expected by YE20 and PDP net of debt underpinning a valuation above where the stock trades, we view BCEI as a rare SMID value opportunity which also benefits from low leverage risk… BCEI lacks the scale required to land itself amongst the ranks of Shale 3.0 operators, but in our opinion, this might not necessarily matter given the clear value disconnect… an unlevered balance sheet provides significant dry powder to transact in a market ripe with distress-driven opportunities. EPS was just 5 cents in Q1, but jumped to 20 cents in Q2 and is forecast to hit 38 cents in Q3. Enter your email to receive our newsletter. Molecular Partners has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics across multiple therapeutic areas. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. High and growing revenue has attracted investment cash, and PayPal boasts a market cap of nearly $228 billion.Despite everything that has hit the markets this year, 2020 is turning out to be a great year for the company. We are highly committed to move to patients as rapidly as possible, building upon our strong preclinical data that shows potential best in class potency in neutralizing live virus," says Patrick Amstutz, CEO of Molecular Partners. The content is intended to be used for informational purposes only. This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. (To watch Bienvenu’s track record, click here)With 6 recent reviews, including 4 Buy and 2 Hold, Darling gets a Moderate Buy rating from the analyst consensus. The shares are selling for $194.61, and have an average price target of $220.27. The company has its hands in broadband internet, mobile services, telephone services, and broadcast video, along with other entertainment services, and its main presence reflects its name: it is most active in Chile, Colombia, Central America, Puerto Rico, and the Caribbean. The analyst concluded: “While a smaller-cap operator, we believe NOG’s limited beta to near-term oil price volatility provides strong FCF assurance, while a strong (and improving) balance sheet brings optionality to capitalize in a buyer-short market.”To this end, Hughes gives NOG shares an Overweight rating (i.e. Apple silicon is ramping and will fuel the momentum in 4Q20 too. EV stocks have soared 500%, 800%, even 1,000% this year. A, HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Share price has been volatile, and has not yet recovered from losses sustained early in the crisis. For more information regarding Molecular Partners AG, go to: www.molecularpartners.com. Actual performance may differ significantly from backtested performance. The stock’s 12 reviews include 11 Buys and 1 Hold. Certain assumptions have been made for modeling purposes and are unlikely to be realized. And that confidence attracted some strong insider buys during the Latin American recent stock sale. This figure implies a potential upside of 38% for the coming year. With state-of-the-art manufacturing facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan, AGC Biologics has decades of experience in CDMO manufacturing, including commercial market supplies with FDA, PDMA and EMA approvals. Seth Lewis, SVP IR, Comms, & Strategyseth.lewis@molecularpartners.comTel: +1 781 420 2361, Lisa Raffensperger, International Medialisa@tenbridgecommunications.comTel: +1 617 903 8783, Thomas Schneckenburger, IR & Mediathomas.schneckenburger@molecularpartners.comTel: +41 79 40799522. (Bloomberg) -- Taiwan Semiconductor Manufacturing Co. reported a stronger-than-expected 22% rise in quarterly sales, buoyed by orders from its largest customers including Apple Inc.The world’s largest contract chipmaker saw revenue for the three months to September climb to a record NT$356.4 billion ($12.4 billion), up from NT$293 billion a year earlier, according to Bloomberg calculations based on monthly sales data disclosed by TSMC. MediaTek, which also counts Huawei as one of its largest customers, reported monthly revenue jumped 61%, helping to lift third-quarter sales to NT$97.3 billion. The DARPin® platform is a fast and cost-effective drug discovery engine, producing drug candidates with optimized properties for development and very high production yields. Molecular Partners AG announced on Monday that it has completed initial manufacturing runs of its tri-specific, antiviral DARPin candidate for COVID-19, named MP0420. At the same time, the stock has managed to retain its value; shares are trading now at the same level they were before their ‘corona collapse’ in early March.The second quarter also saw capital expenditures come in at the low end of guidance, and debt fall to $58 million. The DARPin® platform is a fast and cost-effective drug discovery engine, producing drug candidates with optimized properties for development and very high production yields. Research performed by Molecular Partners in collaboration with virologists at the Spiez Laboratory, a division of the Swiss Federal Office for Civil Protection, has characterized hundreds of monospecific and multispecific DARPin® proteins with strong binding and neutralizing qualities against multiple epitopes on the SARS-CoV-2 spike protein that are crucial for infection. The top line came in at $693 million and $727 million for Q1 and Q2, in line with the previous two quarters. About AGC Biologics:AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service to clients and partners. The company has compounds in various stages of clinical and preclinical development with a focus on oncology. Charles Schwab closed its purchase of online brokerage rival TD Ameritrade Tuesday. Fellow Taiwanese chipmakers United Microelectronics Corp. and MediaTek Inc. on Thursday also reported strong sales, suggesting a broad recovery in the industry.TSMC in July raised its 2020 outlook, saying that revenue this year will grow by more than 20% in dollar terms. Fortunes will be made and lost. (To watch Richard’s track record, click here)In his comments, the 5-star analyst paints a gloomy picture of Intel’s future.“INTC expects 2H to be down Y/Y. Molecular Partners AG announced on Monday that it has completed initial manufacturing runs of its tri-specific, antiviral DARPin candidate for COVID-19, named MP0420. The company has engineered these proteins into trispecific antiviral candidates that target three parts of the viral "spike" protein, which is essential for viral entry into human cells. Cision Distribution 888-776-0942 Analysts believe these seven tech stocks are currently cheap. If you get greedy, and start chasing money, you’ll overlook the signs that tell you when to buy or sell. This company, holding dual headquarters in both the Netherlands and Texas, was ranked 14 out of the top 15 semiconductor companies in 2019, counting by total sales (NXP saw $8.86 billion in sales last year). And the company ended the second quarter with no debt and unrestricted cash on hand of $218 million. Â, Related News:Johnson & Johnson Kicks Off Phase 2 Covid-19 Vaccine Trial In Spain – ReportPfizer CEO: Our Covid-19 Vaccine Could Be Ready In US By Year-EndMedtronic’s First-Of-Its Kind Diabetes System For Young Children Approved. Our technology will match you with the best lenders at super low rates. The factors are averaged together, and given as a single-digit score, on a scale from 1 to 10, letting investors know at a glance the likely way forward for a stock.And a perfect Smart Score, a 10, is a signal that investors should pay attention to. AGC Biologics and Molecular Partners AG will work together to develop their multi-specific DARPin anti-COVID-19 program, MP0420. Revenues remain stable, between $19 and $20 billion per quarter, but EPS has been sliding since Q4 of last year. With $2.9 billion in total sales last year, the company didn’t make into the list of the top 15 chip makers – but it’s still an important player, operating in over a dozen countries around the world and partnering with major names like Samsung and Nokia.Marvell’s partnerships are boosting the company’s position in the growing market for 5G compatible chips. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. (See Darling’s stock analysis at TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. Molecular said that following the completion, it now expects to start first-in-human clinical trials in November this year. Here are the details on three such stocks, along with corroborative commentary from the analysts.ANGI Homeservices (ANGI)First up is a tech company in the internet services niche. Thank you for your feedback. Each is up at least 30% year-to-date, and has a Perfect 10 from the Smart Score. One signal that has been correlated with a stock’s future performance is insider activity. The Smart Score is a data analysis tool, which uses the real-time information collected in the database. But markets change. Changes in these assumptions may have a material impact on the backtested returns presented. For the third quarter, projections are a 2 cent per share profit.The stock’s price appreciation has also borne out the company’s strong position. (See NXPI stock analysis on TipRanks)Intel Corporation (INTC)Our last stock is a big stick in the chip world. Share prices started falling at the end of February and beginning of March, and have failed to regain traction since. Continental produced 340K barrel of oil equivalent per day last year, producing over $4.63 billion in total revenue.